肝癌电子杂志 ›› 2023, Vol. 10 ›› Issue (4): 1-14.
• 指南与共识 • 下一篇
中国医疗保健国际交流促进会肝脏肿瘤学分会, 中国抗癌协会肝癌专业委员会, 中国医师协会肝癌专业委员会, 中国研究型医院学会肝病专业委员会
收稿日期:2023-11-17
出版日期:2023-12-31
发布日期:2024-02-05
通讯作者:
蔡建强,E-mail：caijianqiang@cicams.ac.cn
基金资助:
Received:2023-11-17
Online:2023-12-31
Published:2024-02-05
中国医疗保健国际交流促进会肝脏肿瘤学分会, 中国抗癌协会肝癌专业委员会, 中国医师协会肝癌专业委员会, 中国研究型医院学会肝病专业委员会. 肝细胞癌新辅助及转化治疗中国专家共识（2023版）[J]. 肝癌电子杂志, 2023, 10(4): 1-14.
| [1] 中国抗癌协会肝癌专业委员会转化治疗协作组. 肝癌转化治疗中国专家共识(2021版)[J]. 中华消化外科杂志, 2021, 20(6): 600-616. [2] 海峡两岸医药卫生交流协会肿瘤防治专家委员会. 肝癌肝切除围手术期管理中国专家共识(2021年版)[J]. 中华肿瘤杂志, 2021, 43(4): 414-430. [3] WEN T, JIN C, FACCIORUSSO A, et al.Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensus[J]. Hepatobiliary Surg Nutr, 2018, 7(5): 353-371. [4] HUNG I F, POON R T, LAI C L, et al.Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection[J]. Am J Gastroenterol, 2008, 103(7): 1663-1673. [5] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J/CD]. 肝癌电子杂志, 2020, 7(1): 5-23. [6] 肖永胜, 郭磊, 周俭. 原发性肝癌新辅助治疗进展[J]. 腹部外科, 2021, 34(1): 1-3, 9. [7] SU Y Y, LI C C, LIN Y J, et al.Adjuvant versus neoadjuvant immunotherapy for hepatocellular carcinoma: clinical and immunologic perspectives[J]. Semin Liver Dis, 2021, 41(3): 263-276. [8] SI T, CHEN Y, MA D, et al.Preoperative transarterial chemoembolization for resectable hepatocellular carcinoma in Asia area: a meta-analysis of random controlled trials[J]. Scand J Gastroenterol, 2016, 51(12): 1512-1519. [9] QI X, LIU L, WANG D, et al.Hepatic resection alone versus in combination with pre- and post-operative transarterial chemoembolization for the treatment of hepatocellular carcinoma: a systematic review and meta-analysis[J]. Oncotarget, 2015, 6(34): 36838-36859. [10] MI S, NIE Y, XIE C.Efficacy and safety of preoperative transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis[J]. Scand J Gastroenterol, 2022, 57(9): 1070-1079. [11] MO A, ZHANG Q, XIA F, et al.Preoperative transcatheter arterial chemoembolization and prognosis of patients with solitary large hepatocellular carcinomas (≥5 cm): multicenter retrospective study[J]. Cancer Med, 2023, 12(7): 7734-7747. [12] GUO C, ZHANG J, HUANG X, et al.Preoperative sintilimab plus transarterial chemoembolization for hepatocellular carcinoma exceeding the Milan criteria: a phase Ⅱ trial[J]. Hepatol Commun, 2023, 7(3): e0054. [13] WEI W, LI S, ZHAO R, et al.Neoadjuvant hepatic arterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria: a multi-center, phase 3, randomized, controlled clinical trial[J]. J Clin Oncol, 2023, 41(16 Suppl): 4023. [14] XIA Y, WANG P, PU L, et al.Preliminary efficacy and safety of perioperative treatment of camrelizumab combined with apatinib in resectable hepatocellular carcinoma (HCC): a prospective phase Ⅱ study[J]. J Clin Oncol, 2021, 39(15 Suppl): 4082. [15] HO W J, ZHU Q, DURHAM J, et al.Neoadjuvant cabozantinib and nivolumab converts locally advanced HCC into resectable disease with enhanced antitumor immunity[J]. Nat Cancer, 2021, 2(9): 891-903. [16] SHI Y H, JI Y, LIU W R, et al.A phase Ⅰb/Ⅱ, open-label study evaluating the efficacy and safety of toripalimab injection (js001) or combination with lenvatinib as a neoadjuvant therapy for patients with resectable hepatocellular carcinoma (HCC)[J]. Cancer Res, 2021, 81(13 Suppl): 486. [17] D'ALESSIO A, PAI M, SPALDING D, et al. Neoadjuvant immunotherapy with ipilimumab plus nivolumab and radiologically and pathologically quantifiable responses through modulation of the tumour microenvironment in resectable hepatocellular carcinoma[J]. J Clin Oncol, 41(16 Suppl): 4129. [18] KASEB A O, HASANOV E, CAO H S T, et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2022, 7(3): 208-218. [19] BAI X.A multicenter randomized controlled trial of perioperative versus postoperative camrelizumab plus apatinib for resectable hepatocellular carcinoma[J]. Ann Oncol, 2022, 33(7 Suppl): S323-S330. [20] ZHOU J, FAN J, GU F M, et al.A phase Ⅱ/Ⅲ study of camrelizumab plus apatinib as perioperative treatment of resectable hepatocellular carcinoma at intermediate-high risk of recurrence: primary results of major pathologic response from phase Ⅱ stage[J]. J Clin Oncol, 2023, 41(16 Suppl): 4126. [21] CUI Y, BAO X, YU G, et al.Camrelizumab in combination with apatinib as a perioperative treatment for patients with hepatocellular carcinoma at high risk of recurrence: a prospective, single-arm, phase 2 study[J]. J Clin Oncol, 2023, 41(16 Suppl): 4120. [22] SONG T.A prospective, single-arm, phase Ⅱ clinical study of tislelizumab in combination with lenvatinib for perioperative treatment of resectable primary hepatocellular carcinoma with high risk of recurrence[J]. J Clin Oncol, 2023, 41(16 Suppl): e16218. [23] WU J Y, WU J Y, LI Y N, et al.Lenvatinib combined with anti-PD-1 antibodies plus transcatheter arterial chemoembolization for neoadjuvant treatment of resectable hepatocellular carcinoma with high risk of recurrence: a multicenter retrospective study[J]. Front Oncol, 2022, 12: 985380. [24] WU F, CHEN B, DONG D, et al.Phase 2 evaluation of neoadjuvant intensity-modulated radiotherapy in centrally located hepatocellular carcinoma: a nonrandomized controlled trial[J]. JAMA Surg, 2022, 157(12): 1089-1096. [25] LIN H, LI X, LIU Y, et al.Neoadjuvant radiotherapy provided survival benefit compared to adjuvant radiotherapy for hepatocellular carcinoma[J]. ANZ J Surg, 2018, 88(10): E718-E724. [26] LEE H A, SEO Y S, SHIN I S, et al.Efficacy and feasibility of surgery and external radiotherapy for hepatocellular carcinoma with portal invasion: a meta-analysis[J]. Int J Surg, 2022, 104: 106753. [27] 周俭, 彭远飞, 王征. 余肝不足肝癌手术治疗争议与共识[J]. 中国实用外科杂志, 2018, 38(2): 126-132. [28] ZHANG Y, HUANG G, WANG Y, et al.Is salvage liver resection necessary for initially unresectable hepatocellular carcinoma patients downstaged by transarterial chemoembolization? Ten years of experience[J]. Oncologist, 2016, 21(12): 1442-1449. [29] SHI F, WU M, LIAN S S, et al.Radiofrequency ablation following downstaging of hepatocellular carcinoma by using transarterial chemoembolization: long-term outcomes[J]. Radiology, 2019, 293(3): 707-715. [30] CAI L, LI H, GUO J, et al.Drug-eluting bead transarterial chemoembolization is an effective downstaging option for subsequent radical treatments in patients with hepatocellular carcinoma: a cohort study[J]. Clin Res Hepatol Gastroenterol, 2021, 45(4): 101535. [31] LI H, WU F, DUAN M, et al.Drug-eluting bead transarterial chemoembolization (TACE) vs conventional TACE in treating hepatocellular carcinoma patients with multiple conventional TACE treatments history: a comparison of efficacy and safety[J]. Medicine (Baltimore), 2019, 98(21): e15314. [32] LI Q J, HE M K, CHEN H W, et al.Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase Ⅲ trial[J]. J Clin Oncol, 2022, 40(2): 150-160. [33] LI B, QIU J, ZHENG Y, et al.Conversion to resectability using transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for initially unresectable hepatocellular carcinoma[J]. Ann Surg Open, 2021, 2(2): e057. [34] KOLLIGS F T, BILBAO J I, JAKOBS T, et al.Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma[J]. Liver Int, 2015, 35(6): 1715-1721. [35] SUN H C, ZHU X D, HUANG C, et al.Initially unresectable hepatocellular carcinoma treated by combination therapy of tyrosine kinase inhibitor and anti-PD-1 antibody followed by resection[J]. J Clin Oncol, 2020, 38(15 Suppl): e16690. [36] SUN H C, ZHU X D, HUANG C, et al.Combination therapy with lenvatinib and anti-PD-1 antibodies for unresectable or advanced hepatocellular carcinoma: a real-world study[J]. J Clin Oncol, 2020, 38(15 Suppl): e16610. [37] ZHANG W, TONG S, HU B, et al.Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase Ⅱ trial[J]. J Immunother Cancer, 2023, 11(9): e007366. [38] TADA M, ICHIDA A, ARITA J, et al.Multicenter prospective study to evaluate the efficacy of lenvatinib to achieve conversion surgery for initially unresectable hepatocellular carcinoma: LENS-HCC trial[J]. J Clin Oncol, 2023, 40(4 Suppl): 458. [39] WANG L, WANG H, CUI Y, et al.Sintilimab plus lenvatinib conversion therapy for intermediate/locally advanced hepatocellular carcinoma: a phase 2 study[J]. Front Oncol, 2023, 13: 1115109. [40] SUN H, ZHU X, GAO Q, et al.Sintilimab combined with bevacizumab biosimilar as a conversion therapy in potentially resectable intermediate-stage hepatocellular carcinoma (HCC): Updated results of a phase Ⅱ trial[J]. J Clin Oncol, 2023, 41(16 Suppl): e16220. [41] 李川江, 周杰. 肝细胞肝癌经肝动脉化疗栓塞联合索拉非尼降期后二期切除的初步报告[J]. 腹部外科, 2017, 30(4): 295-298, 301. [42] HE M K, LI Q J, ZOU R H, et al.Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial[J]. JAMA Oncol, 2019, 5(7): 953-960. [43] HE M K, ZOU R H, LI Q J, et al.Phase Ⅱ study of sorafenib combined with concurrent hepatic arterial infusion of oxaliplatin, 5-fluorouracil and leucovorin for unresectable hepatocellular carcinoma with major portal vein thrombosis[J]. Cardiovasc Intervent Radiol, 2018, 41(5): 734-743. [44] ZHANG T, ZHANG J L, ZHANG X H, et al.Triple combination therapy comprising angiogenesis inhibitors, anti-PD-1 antibodies, and hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma[J]. J Clin Oncol, 2021, 39(15 Suppl): e16124. [45] HE M K, LIANG R B, ZHAO Y, et al.Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma[J]. Ther Adv Med Oncol, 2021, 13: 17588359211002720. [46] ZHANG X, ZHU X, FENG X, et al.The safety and efficacy of lenvatinib combined with TACE and PD-1 inhibitors (Len-TAP) versus TACE alone in the conversion resection for initially unresectable hepatocellular carcinoma: interim results from a multicenter prospective cohort study[J]. Ann Oncol, 2022, 33(7 Suppl): S323-S330. [47] GAN L, LANG M, TIAN X, et al.A retrospective analysis of conversion therapy with lenvatinib, sintilimab, and arterially-directed therapy in patients with initially unresectable hepatocellular carcinoma[J]. J Hepatocell Carcinoma, 2023, 10: 673-686. [48] ZHANG Z, YAN M, CHEN Y, et al.Transarterial chemoembolization combined with lenvatinib and camrelizumab for unresectable hepatocellular carcinoma: a prospective, single-arm, multicenter study[J]. J Clin Oncol, 2023, 41(16 Suppl): 4072. [49] TAN K, HE X, ZHANG H, et al.Efficacy and safety of tislelizumab combined with lenvatinib and FOLFOX4-HAIC in conversion therapy of middle-advanced stage hepatocellular carcinoma (HCC): a real-world retrospective study[J]. J Clin Oncol, 2023, 41(16 Suppl): e16137. [50] HONG Z, LEI G, SONG B, et al.Donafenib, anti-PD-1 antibodies, plus hepatic arterial infusion chemotherapy (HAIC) as conversion therapy in patients with initially unresectable hepatocellular carcinoma (HCC): a prospective, single-arm, phase 2 study[J]. J Clin Oncol, 2023, 41(16 Suppl): e16140. [51] DONG W, ZHANG S, HUO Z, et al.Lenvatinib in combination with PD-1 inhibitor and hepatic arterial infusion chemotherapy (HAIC) for patients with potentially resectable hepatocellular carcinoma: a retrospective analysis[J]. J Clin Oncol, 2023, 41(16 Suppl): e16160. [52] WEI X, JIANG Y, ZHANG X, et al.Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study[J]. J Clin Oncol, 2019, 37(24): 2141-2151. [53] CHEN B, LI Y X, WANG L, et al.Phase Ⅱ study of concurrent sorafenib and radiotherapy for advanced hepatocellular carcinoma with portal vein and/or hepatic vein tumor thrombosis[J]. Int J Radiat Oncol Biol Phys, 2021, 111(3 Suppl 1): S39. [54] WEI Z, ZHAO J, BI X, et al.Neoadjuvant radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a systematic review[J]. Hepatobiliary Surg Nutr, 2022, 11(5): 709-717. [55] KIM J, CHENG J C, NAM T K, et al.Efficacy of liver-directed combined radiotherapy in locally advanced hepatocellular carcinoma with portal vein tumor thrombosis[J]. Cancers (Basel), 2023, 15(12): 3164. [56] LEE H S, CHOI G H, CHOI J S, et al.Surgical resection after down-staging of locally advanced hepatocellular carcinoma by localized concurrent chemoradiotherapy[J]. Ann Surg Oncol, 2014, 21(11): 3646-3653. [57] MAZZAFERRO V, REGALIA E, DOCI R, et al.Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis[J]. N Engl J Med, 1996, 334(11): 693-699. [58] YAO F Y, FERRELL L, BASS N M, et al.Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival[J]. Hepatology, 2001, 33(6): 1394-1403. [59] LEI J Y, WANG W T, YAN L N.Up-to-seven criteria for hepatocellular carcinoma liver transplantation: a single center analysis[J]. World J Gastroenterol, 2013, 19(36): 6077-6083. [60] KAIDO T, OGAWA K, MORI A, et al.Usefulness of the Kyoto criteria as expanded selection criteria for liver transplantation for hepatocellular carcinoma[J]. Surgery, 2013, 154(5): 1053-1060. [61] DUBAY D, SANDROUSSI C, SANDHU L, et al.Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion[J]. Ann Surg, 2011, 253(1): 166-172. [62] ZHENG S S, XU X, WU J, et al.Liver transplantation for hepatocellular carcinoma: Hangzhou experiences[J]. Transplantation, 2008, 85(12): 1726-1732. [63] ULAHANNAN S V, DUFFY A G, MCNEEL T S, et al.Earlier presentation and application of curative treatments in hepatocellular carcinoma[J]. Hepatology, 2014, 60(5): 1637-1644. [64] SILVA M F, SHERMAN M.Criteria for liver transplantation for HCC: what should the limits be?[J]. J Hepatol, 2011, 55(5): 1137-1147. [65] YAO F Y, KERLAN R J, HIROSE R, et al.Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis[J]. Hepatology, 2008, 48(3): 819-827. [66] MEHTA N, GUY J, FRENETTE C T, et al.Excellent outcomes of liver transplantation following down-staging of hepatocellular carcinoma to within milan criteria: a multicenter study[J]. Clin Gastroenterol Hepatol, 2018, 16(6): 955-964. [67] KARDASHIAN A, FLORMAN S S, HAYDEL B, et al.Liver transplantation outcomes in a U.S. multicenter cohort of 789 patients with hepatocellular carcinoma presenting beyond Milan criteria[J]. Hepatology, 2020, 72(6): 2014-2028. [68] HEIMBACH J K, KULIK L M, FINN R S, et al.AASLD guidelines for the treatment of hepatocellular carcinoma[J]. Hepatology, 2018, 67(1): 358-380. [69] YAO F Y, MEHTA N, FLEMMING J, et al.Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria[J]. Hepatology, 2015, 61(6): 1968-1977. [70] RAVAIOLI M, GRAZI G L, PISCAGLIA F, et al.Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria[J]. Am J Transplant, 2008, 8(12): 2547-2557. [71] OTTO G, HERBER S, HEISE M, et al.Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma[J]. Liver Transpl, 2006, 12(8): 1260-1267. [72] AFFONSO B B, GALASTRI F L, DA MOTTA LEAL FILHO J M, et al. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging[J]. World J Gastroenterol, 2019, 25(37): 5687-5701. [73] LI H Z, TAN J, TANG T, et al.Chemoembolization plus microwave ablation vs chemoembolization alone in unresectable hepatocellular carcinoma beyond the Milan criteria: a propensity scoring matching study[J]. J Hepatocell Carcinoma, 2021, 8: 1311-1322. [74] LEWANDOWSKI R J, KULIK L M, RIAZ A, et al.A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization[J]. Am J Transplant, 2009, 9(8): 1920-1928. [75] FRANKUL L, FRENETTE C.Hepatocellular carcinoma: downstaging to liver transplantation as curative therapy[J]. J Clin Transl Hepatol, 2021, 9(2): 220-226. [76] TRAN N H, MUNOZ S, THOMPSON S, et al.Hepatocellular carcinoma downstaging for liver transplantation in the era of systemic combined therapy with anti-VEGF/TKI and immunotherapy[J]. Hepatology, 2022, 76(4): 1203-1218. [77] LLOVET J M, RICCI S, MAZZAFERRO V, et al.Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359(4): 378-390. [78] CHENG A L, KANG Y K, CHEN Z, et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phaseⅢ randomised, double-blind, placebo-controlled trial[J]. Lancet Oncal, 2009, 10(1): 25-34. [79] KUDO M, FINN R, QIN S, et al.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126): 1163-1173. [80] KUDO M, UESHIMA K, YOKOSUKA O, et al.Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2018, 3(6): 424-432. [81] KUDO M, FINN R, QIN S, et al.Analysis of survival and objective response (OR) in patients with hepatocellular carcinoma in a phase Ⅲ study of lenvatinib (REFLECT)[J]. J Clin Oncol, 2019, 37(4 Suppl): 186. [82] VINCENZI B, DI MAIO M, SILLETTA M, et al.Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with locoregional therapies: a literature-based meta-analysis[J]. PLoS One, 2015, 10(7): e0133488. [83] JUNG E S, KIM J H, YOON E L, et al.Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization[J]. J Hepatol, 2013, 58(6): 1181-1187. [84] 中华人民共和国国家卫生健康委员会医政司. 原发性肝癌诊疗指南(2022 年版)[J/CD]. 肝癌电子杂志, 2022, 9(1): 1-22. [85] PARK H, PARK J Y.Clinical significance of AFP and PIVKA-Ⅱ responses for monitoring treatment outcomes and predicting prognosis in patients with hepatocellular carcinoma[J]. Biomed Res Int, 2013: 310427. [86] EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER, EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2012, 56(4): 908-943. [87] XU J, LI J, CHEN J, et al.Effect of adjuvant interferon therapy on hepatitis b/c virus-related hepatocellular carcinoma after curative therapy-meta-analysis[J]. Adv Clin Exp Med, 2015, 24(2): 331-340. [88] XIA B W, ZHANG Y C, WANG J, et al.Efficacy of antiviral therapy with nucleotide/nucleoside analogs after curative treatment for patients with hepatitis B virus-related hepatocellular carcinoma: a systematic review and meta-analysis[J]. Clin Res Hepatol Gastroenterol, 2015, 39(4): 458-468. [89] MANTHRAVADI S, PALETI S, PANDYA P.Impact of sustained viral response postcurative therapy of hepatitis C-related hepatocellular carcinoma: a systematic review and meta-analysis[J]. Int J Cancer [90] FINN R S, QIN S, IKEDA M, et al.Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382(20): 1894-1905. [91] QIN S, REN Z, FENG Y H, et al.Atezolizumab plus bevacizumab versus sorafenib in the Chinese subpopulation with unresectable hepatocellular carcinoma: phase 3 randomized, open-label IMbrave150 study[J]. liver Cancer, 2021, 10(4): 296-308. [92] KELLEY R K, RIMASSA L, CHENG A L, et al.Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2022, 23(8): 995-1008. [93] KUDO M.Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma[J]. Hepatobiliary Surg Nutr, 2022, 11(4): 592-596. [94] YAU T, PARK J W, FINN R S, et al.Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial[J]. Lancet Oncol, 2022, 23(1): 77-90. [95] LLOVET J M, KUDO M, MERLE P, et al.Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial[J]. Lancet Oncol, 2023, 24(12): 1399-410. [96] PENG Z, FAN W, ZHU B, et al.Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase Ⅲ, randomized clinical trial (LAUNCH)[J]. J Clin Oncol, 2023, 41(1): 117-127. [97] REN Z, XU J, BAI Y, et al.Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study[J]. Lancet Oncol, 2021, 22(7): 977-990. [98] QIN S, BI F, GU S, et al.Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: a randomized, open-label, parallel-controlled phase Ⅱ-Ⅲ trial[J]. J Clin Oncol, 2021, 39(27): 3002-3011. [99] QIN S, KUDO M, MEYER T, et al.LBA36 final analysis of RATIONALE-301: randomized, phase 3 study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma[J]. Ann Oncol, 2022, 33(Suppl): 1402-1403. [100] QIN S, CHAN S L, GU S, et al.Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study[J]. Lancet, 2023, 402(10408): 1133-1146. [101] EISENHAUER E A, THERASSE P, BOGAERTS J, et al.New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45: 228-247. [102] LENCIONI R, LLOVET JM.Modified RECIST (mRECIST) assessment for hepatocellular carcinoma[J]. Semin Liver Dis, 2010, 30: 52-60. [103] LLOVET JM, LENCIONI R. mRECIST for HCC: performance and novel refinements[J]. J Hepatol, 2020, 72: 288-306. |
| No related articles found! |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
